MNK Proteins as Therapeutic Targets in Leukemia

References

• Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997;16(8):1909–1920. doi:10.1093/emboj/16.8.1909
   PubMed Web of Science ®Google Scholar
• Bonneau AM, Sonenberg N. Involvement of the 24-kDa cap-binding protein in regulation of protein synthesis in mitosis. J Biol Chem. 1987;262(23):11134–11139. doi:10.1016/S0021-9258(18)60935-4
   PubMed Web of Science ®Google Scholar
• Morley SJ, McKendrick L. Involvement of stress-activated protein kinase and p38/RK mitogen-activated protein kinase signaling pathways in the enhanced phosphorylation of initiation factor 4E in NIH 3T3 cells. J Biol Chem. 1997;272(28):17887–17893. doi:10.1074/jbc.272.28.17887
   PubMed Web of Science ®Google Scholar
• Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539–6549. doi:10.1128/MCB.24.15.6539-6549.2004
   PubMed Web of Science ®Google Scholar
• Ueda T, Sasaki M, Elia AJ, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A. 2010;107(32):13984–13990. doi:10.1073/pnas.1008136107
   PubMed Web of Science ®Google Scholar
• Kosciuczuk EM, Saleiro D, Platanias LC. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia. Cytokine. 2017;89:116–121. doi:10.1016/j.cyto.2016.01.024
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang H, Wang S, et al. Optimization of 4,6-disubstituted pyrido[3,2-d]pyrimidines as dual MNK/PIM inhibitors to inhibit leukemia cell growth. J Med Chem. 2021;64(18):13719–13735. doi:10.1021/acs.jmedchem.1c01084
   PubMed Web of Science ®Google Scholar
• Yen SC, Chen LC, Huang HL, et al. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorg Chem. 2022;121:105675. doi:10.1016/j.bioorg.2022.105675
   PubMed Web of Science ®Google Scholar
• Suarez M, Blyth GT, Mina AA, et al. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget. 2021;12(10):955–966. doi:10.18632/oncotarget.27952
   PubMedGoogle Scholar
• Therapeutics E. A phase 1–2 dose-escalation and cohort-expansion study of oral tomivosertib (eFT-508) in subjects with hematological malignancies; 2017. Available from: https://ClinicalTrials.gov/show/NCT02937675. Accessed April 11, 2023.
   Google Scholar
• EDDC ASRE, Inc. CI. Evaluation of ETC-1907206 with dasatinib in advanced haematologic malignancies; 2018. Available from: https://ClinicalTrials.gov/show/NCT03414450. Accessed April 11, 2023.
   Google Scholar
• Jacqueline Garcia M, Lilly E; Company, Institute D-FC. Combination merestinib and LY2874455 for patients with relapsed or refractory acute myeloid leukemia; 2017. Available from: https://ClinicalTrials.gov/show/NCT03125239. Accessed April 11, 2023.
   Google Scholar
• American Cancer Society. Cancer Facts & Figures. American Cancer Society; 2022.
   Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398
   PubMed Web of Science ®Google Scholar
• Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12(11):161. doi:10.1038/s41408-022-00756-9
   PubMed Web of Science ®Google Scholar
• Kay NE, Parikh SA, Parikh SA. Early intervention in asymptomatic chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2021;19(2):92–103.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Treating Acute Lymphocytic Leukemia (ALL). American Cancer Society; 2021.
   Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385–1415. doi:10.6004/jnccn.2020.0047
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749. doi:10.6004/jnccn.2019.0028
   PubMed Web of Science ®Google Scholar
• Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2022;10:e46–e58.
   PubMed Web of Science ®Google Scholar
• Administration FaD. FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation. Administration FaD; 2023:ed2022.
   Google Scholar
• Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129(26):3403–3406. doi:10.1182/blood-2017-05-782292
   PubMed Web of Science ®Google Scholar
• Estey E, Karp JE, Emadi A, Othus M, Gale RP. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020;34(3):671–681. doi:10.1038/s41375-019-0704-5
   PubMed Web of Science ®Google Scholar
• Fukunaga R, Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 1997;16(8):1921–1933. doi:10.1093/emboj/16.8.1921
   PubMed Web of Science ®Google Scholar
• Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci. 2008;13(14):5359–5374. doi:10.2741/3086
   PubMedGoogle Scholar
• Scheper GC, Morrice NA, Kleijn M, Proud CG. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol. 2001;21(3):743–754. doi:10.1128/MCB.21.3.743-754.2001
   PubMed Web of Science ®Google Scholar
• Li Y, Yue P, Deng X, et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia. 2010;12(10):848–855. doi:10.1593/neo.10704
   PubMed Web of Science ®Google Scholar
• Orton KC, Ling J, Waskiewicz AJ, et al. Phosphorylation of Mnk1 by caspase-activated Pak2/gamma-PAK inhibits phosphorylation and interaction of eIF4G with Mnk. J Biol Chem. 2004;279(37):38649–38657. doi:10.1074/jbc.M407337200
   PubMed Web of Science ®Google Scholar
• Brown MC, Gromeier M. MNK controls mTORC1: substrate association through regulation of TELO2 binding with mTORC1. Cell Rep. 2017;18(6):1444–1457. doi:10.1016/j.celrep.2017.01.023
   PubMed Web of Science ®Google Scholar
• Xie J, Shen K, Jones AT, et al. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cell Mol Life Sci. 2021;78:249–270. doi:10.1007/s00018-020-03491-1
   PubMed Web of Science ®Google Scholar
• Yang X, Zhong W, Cao R. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer. Cell Signal. 2020;73:109689. doi:10.1016/j.cellsig.2020.109689
   PubMed Web of Science ®Google Scholar
• Zhou H, Jia X, Yang FAN. Elevated nuclear phospho-eIF4E body levels are associated with tumor progression and poor prognosis for acute myeloid leukemia. Biocell. 2021;45(3):711–722. doi:10.32604/biocell.2021.014193
   Web of Science ®Google Scholar
• Joshi S, Platanias LC. Mnk kinase pathway: cellular functions and biological outcomes. World J Biol Chem. 2014;5(3):321–333. doi:10.4331/wjbc.v5.i3.321
   PubMedGoogle Scholar
• DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D. Regulation of sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol. 2006;26(5):1898–1907. doi:10.1128/MCB.26.5.1898-1907.2006
   PubMed Web of Science ®Google Scholar
• Edwin F, Anderson K, Patel TB. HECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2. J Biol Chem. 2010;285(1):255–264. doi:10.1074/jbc.M109.030882
   PubMed Web of Science ®Google Scholar
• Buxade M, Morrice N, Krebs DL, Proud CG. The PSF.p54nrb complex is a novel Mnk substrate that binds the mRNA for tumor necrosis factor alpha. J Biol Chem. 2008;283(1):57–65. doi:10.1074/jbc.M705286200
   PubMed Web of Science ®Google Scholar
• Buxade M, Parra JL, Rousseau S, et al. The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity. 2005;23(2):177–189. doi:10.1016/j.immuni.2005.06.009
   PubMed Web of Science ®Google Scholar
• Hefner Y, Borsch-Haubold AG, Murakami M, et al. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem. 2000;275(48):37542–37551. doi:10.1074/jbc.M003395200
   PubMed Web of Science ®Google Scholar
• Bouameur JE, Schneider Y, Begre N, et al. Phosphorylation of serine 4642 in the C-terminus of plectin by MNK2 and PKA modulates its interaction with intermediate filaments. J Cell Sci. 2013;126(Pt 18):4195–4207. doi:10.1242/jcs.127779
   PubMed Web of Science ®Google Scholar
• Manne BK, Campbell RA, Bhatlekar S, et al. MAPK-interacting kinase 1 regulates platelet production, activation, and thrombosis. Blood. 2022;140(23):2477–2489. doi:10.1182/blood.2022015568
   PubMedGoogle Scholar
• Mishra RK, Clutter MR, Blyth GT, et al. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening. Chem Biol Drug Des. 2019;94(4):1813–1823. doi:10.1111/cbdd.13585
   PubMed Web of Science ®Google Scholar
• Jauch R, Jakel S, Netter C, et al. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site. Structure. 2005;13(10):1559–1568. doi:10.1016/j.str.2005.07.013
   PubMed Web of Science ®Google Scholar
• Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50–83. doi:10.1128/MMBR.00031-10
   PubMed Web of Science ®Google Scholar
• Reich SH, Sprengeler PA, Chiang GG, et al. Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) Inhibition. J Med Chem. 2018;61(8):3516–3540. doi:10.1021/acs.jmedchem.7b01795
   PubMed Web of Science ®Google Scholar
• Yang H, Chennamaneni LR, Ho MWT, et al. Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia. J Med Chem. 2018;61(10):4348–4369. doi:10.1021/acs.jmedchem.7b01714
   PubMed Web of Science ®Google Scholar
• Zhan Y, Guo J, Yang W, et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J Clin Invest. 2017;127(11):4179–4192. doi:10.1172/JCI91258
   PubMed Web of Science ®Google Scholar
• Santag S, Siegel F, Wengner AM, et al. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity. Cancer Lett. 2017;390:21–29. doi:10.1016/j.canlet.2016.12.029
   PubMed Web of Science ®Google Scholar
• Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol. 2001;21(16):5500–5511. doi:10.1128/MCB.21.16.5500-5511.2001
   PubMed Web of Science ®Google Scholar
• Yan SB, Peek VL, Ajamie R, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013;31(4):833–844. doi:10.1007/s10637-012-9912-9
   PubMed Web of Science ®Google Scholar
• Kwiatkowski J, Liu B, Pang S, et al. Stepwise evolution of fragment hits against MAPK interacting kinases 1 and 2. J Med Chem. 2020;63(2):621–637. doi:10.1021/acs.jmedchem.9b01582
   PubMed Web of Science ®Google Scholar
• Wang S, Li B, Liu B, et al. Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design. Bioorg Med Chem. 2018;26(16):4602–4614. doi:10.1016/j.bmc.2018.05.004
   PubMed Web of Science ®Google Scholar
• Diab S, Teo T, Kumarasiri M, et al. Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. ChemMedChem. 2014;9(5):962–972. doi:10.1002/cmdc.201300552
   PubMed Web of Science ®Google Scholar
• Jin X, Merrett J, Tong S, et al. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold. Eur J Med Chem. 2019;162:735–751. doi:10.1016/j.ejmech.2018.10.070
   PubMed Web of Science ®Google Scholar
• Kannan S, Poulsen A, Yang HY, et al. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations. Biochemistry. 2015;54(1):32–46. doi:10.1021/bi501261j
   PubMed Web of Science ®Google Scholar
• Kannan S, Pradhan MR, Cherian J, et al. Small molecules targeting the inactive form of the Mnk1/2 kinases. ACS Omega. 2017;2(11):7881–7891. doi:10.1021/acsomega.7b01403
   PubMed Web of Science ®Google Scholar
• Xu W, Kannan S, Verma CS, Nacro K. Update on the development of MNK inhibitors as therapeutic agents. J Med Chem. 2022;65(2):983–1007. doi:10.1021/acs.jmedchem.1c00368
   PubMed Web of Science ®Google Scholar
• Bou-Petit E, Hummer S, Alarcon H, et al. Overcoming paradoxical kinase priming by a novel MNK1 inhibitor. J Med Chem. 2022;65(8):6070–6087. doi:10.1021/acs.jmedchem.1c01941
   PubMed Web of Science ®Google Scholar
• Hantschel O. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors. ACS Chem Biol. 2015;10(1):234–245. doi:10.1021/cb500886n
   PubMed Web of Science ®Google Scholar
• Abdelaziz AM, Basnet SKC, Islam S, et al. Synthesis and evaluation of 2’H-spiro[cyclohexane-1,3’-imidazo[1,5-a]pyridine]-1’,5’-dione derivatives as Mnk inhibitors. Bioorg Med Chem Lett. 2019;29(18):2650–2654. doi:10.1016/j.bmcl.2019.07.043
   PubMed Web of Science ®Google Scholar
• Abdelaziz AM, Diab S, Islam S, et al. Discovery of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent Mnk2 inhibitors: design, synthesis, SAR analysis, and evaluation of in vitro anti-leukaemic activity. Med Chem. 2019;15(6):602–623. doi:10.2174/1573406415666181219111511
   PubMed Web of Science ®Google Scholar
• Matsui Y, Yasumatsu I, Yoshida KI, et al. A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1. Acta Crystallogr Struct Biol Commun. 2018;74(Pt 3):156–160. doi:10.1107/S2053230X18002108
   PubMedGoogle Scholar
• Sansook S, Lineham E, Hassell-Hart S, et al. Probing the anticancer action of novel ferrocene analogues of MNK inhibitors. Molecules. 2018;23(9):2126. doi:10.3390/molecules23092126
   PubMed Web of Science ®Google Scholar
• Halder AK, Cordeiro M. Multi-target in silico prediction of inhibitors for mitogen-activated protein kinase-interacting kinases. Biomolecules. 2021;11(11):1670. doi:10.3390/biom11111670
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981–2002. J Nat Prod. 2003;66:1022–1037. doi:10.1021/np030096l
   PubMed Web of Science ®Google Scholar
• Cotoraci C, Ciceu A, Sasu A, Miutescu E, Hermenean A. The anti-leukemic activity of natural compounds. Molecules. 2021;26(9):2709. doi:10.3390/molecules26092709
   PubMed Web of Science ®Google Scholar
• Kimira M, Arai Y, Shimoi K, Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol. 1998;8(3):168–175. doi:10.2188/jea.8.168
   PubMedGoogle Scholar
• Bower AM, Real Hernandez LM, Berhow MA, de Mejia EG. Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV. J Agric Food Chem. 2014;62(26):6147–6158. doi:10.1021/jf500639f
   PubMed Web of Science ®Google Scholar
• Shankar E, Goel A, Gupta K, Gupta S. Plant flavone apigenin: an emerging anticancer agent. Curr Pharmacol Rep. 2017;3(6):423–446. doi:10.1007/s40495-017-0113-2
   PubMedGoogle Scholar
• Yen SC, Wu YW, Huang CC, et al. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. Phytomedicine. 2022;100:154061. doi:10.1016/j.phymed.2022.154061
   PubMed Web of Science ®Google Scholar
• Pan H, Hu Q, Wang J, et al. Myricetin is a novel inhibitor of human inosine 5’-monophosphate dehydrogenase with anti-leukemia activity. Biochem Biophys Res Commun. 2016;477(4):915–922. doi:10.1016/j.bbrc.2016.06.158
   PubMed Web of Science ®Google Scholar
• Cai F, Li B, Li J, Ding Y, Xu D, Huang F. Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E. Anticancer Drugs. 2022;34:620–626. doi:10.1097/CAD.0000000000001421
   PubMed Web of Science ®Google Scholar
• Chen LC, Huang HL, HuangFu WC, et al. Biological evaluation of selected flavonoids as inhibitors of MNKs targeting acute myeloid leukemia. J Nat Prod. 2020;83(10):2967–2975. doi:10.1021/acs.jnatprod.0c00516
   PubMed Web of Science ®Google Scholar
• Sugawara F, Strobel S, Strobel G. The structure and biological activity of cercosporamide from Cercosporidium henningsii. J Org Chem. 1991;56:909–910. doi:10.1021/jo00003a002
   Web of Science ®Google Scholar
• Konicek BW, Stephens JR, McNulty AM, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011;71(5):1849–1857. doi:10.1158/0008-5472.CAN-10-3298
   PubMed Web of Science ®Google Scholar
• Wang S, Zang J, Huang M, et al. Discovery of novel (+)-Usnic acid derivatives as potential anti-leukemia agents with pan-Pim kinases inhibitory activity. Bioorg Chem. 2019;89:102971. doi:10.1016/j.bioorg.2019.102971
   PubMed Web of Science ®Google Scholar
• Altman JK, Szilard A, Konicek BW, et al. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood. 2013;121(18):3675–3681. doi:10.1182/blood-2013-01-477216
   PubMed Web of Science ®Google Scholar
• Kosciuczuk EM, Saleiro D, Kroczynska B, et al. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood. 2016;128(3):410–414. doi:10.1182/blood-2016-02-698704
   PubMed Web of Science ®Google Scholar
• Kosciuczuk EM, Kar AK, Blyth GT, et al. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget. 2019;10(67):7112–7121. doi:10.18632/oncotarget.27388
   PubMedGoogle Scholar
• Lim S, Saw TY, Zhang M, et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013;110(25):E2298–2307. doi:10.1073/pnas.1301838110
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li H, Li Q, Hu Q, Liu B. MNK/eIF4E inhibition overcomes anlotinib resistance in non-small cell lung cancer. In: Fundamental and Clinical Pharmacology. Wiley; 2022:1–8.
   Google Scholar
• Grzmil M, Seebacher J, Hess D, et al. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. Cell Signal. 2016;28(9):1412–1421. doi:10.1016/j.cellsig.2016.06.005
   PubMed Web of Science ®Google Scholar
• Yang X, Liu Z, Yin X, Zeng Y, Guo G. Inhibition MNK-eIF4E-beta-catenin preferentially sensitizes gastric cancer to chemotherapy. Fundam Clin Pharmacol. 2022;36(4):712–720. doi:10.1111/fcp.12759
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang C, Li M, Yang X. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer. J Pharm Pharmacol. 2021;73(10):1418–1426. doi:10.1093/jpp/rgab094
   PubMed Web of Science ®Google Scholar
• Altman JK, Glaser H, Sassano A, et al. Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol. 2010;78(4):778–784. doi:10.1124/mol.110.064642
   PubMed Web of Science ®Google Scholar
• Li PDS, Yu M, Adams J, et al. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget. 2016;7(35):56811–56825. doi:10.18632/oncotarget.10796
   PubMedGoogle Scholar
• Chen K, Chen Y, Chen Z, et al. miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells. Onco Targets Ther. 2018;11:3141–3147. doi:10.2147/OTT.S143465
   PubMed Web of Science ®Google Scholar
• Zhang M, Fu W, Prabhu S, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol. 2008;28(20):6496–6509. doi:10.1128/MCB.00477-08
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Y, Lv C, Wang L, Song H. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway. Biochem Biophys Res Commun. 2016;478(2):893–899. doi:10.1016/j.bbrc.2016.08.047
   PubMed Web of Science ®Google Scholar
• Knight JRP, Alexandrou C, Skalka GL, et al. MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discov. 2021;11(5):1228–1247. doi:10.1158/2159-8290.CD-20-0652
   PubMed Web of Science ®Google Scholar
• Fan C, Zhao C, Zhang F, et al. Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition. Proc Natl Acad Sci U S A. 2021;118(1). doi:10.1073/pnas.2020102118
   Web of Science ®Google Scholar
• Huang XB, Yang CM, Han QM, Ye XJ, Lei W, Qian WB. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells. Acta Pharmacol Sin. 2018;39(12):1894–1901. doi:10.1038/s41401-018-0161-0
   PubMed Web of Science ®Google Scholar
• Teo T, Yu M, Yang Y, et al. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells. Cancer Lett. 2015;357(2):612–623. doi:10.1016/j.canlet.2014.12.029
   PubMed Web of Science ®Google Scholar
• Schatz JH, Oricchio E, Wolfe AL, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med. 2011;208(9):1799–1807. doi:10.1084/jem.20110846
   PubMed Web of Science ®Google Scholar
• Mohamed LM, Eltigani MM, Abdallah MH, et al. Discovery of novel natural products as dual MNK/PIM inhibitors for acute myeloid leukemia treatment: pharmacophore modeling, molecular docking, and molecular dynamics studies. Front Chem. 2022;10:975191. doi:10.3389/fchem.2022.975191
   PubMed Web of Science ®Google Scholar
• Wu H, Hu C, Wang A, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016;30(1):173–181. doi:10.1038/leu.2015.180
   PubMed Web of Science ®Google Scholar
• Cherian J, Nacro K, Poh ZY, et al. Structure-activity relationship studies of mitogen activated protein kinase interacting kinase (MNK) 1 and 2 and BCR-ABL1 inhibitors targeting chronic myeloid leukemic cells. J Med Chem. 2016;59(7):3063–3078. doi:10.1021/acs.jmedchem.5b01712
   PubMed Web of Science ®Google Scholar
• Xing K, Zhang J, Han Y, Tong T, Liu D, Zhao L. Design, synthesis and bioactivity evaluation of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as Mnk and HDAC inhibitors. Molecules. 2020;25(18):4318. doi:10.3390/molecules25184318
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019;11(11):1794. doi:10.3390/cancers11111794
   PubMed Web of Science ®Google Scholar
• Oncology TRi, Therapeutics E, Cancer SUT. Safety, pharmacodynamics, pharmacokinetics, and efficacy of tomivosertib combined with paclitaxel in advanced breast cancer; 2020. Available from: https://ClinicalTrials.gov/show/NCT04261218. Accessed April 11, 2023.
   Google Scholar
• Therapeutics E. An open-label study examining the effect of tomivosertib (eFT508) in patients with advanced castrate-resistant prostate cancer (CRPC); 2018. Available from: https://ClinicalTrials.gov/show/NCT03690141. Accessed April 11, 2023.
   Google Scholar
• Therapeutics E. Tomivosertib (eFT-508) in combination with PD-1/PD-L1 inhibitor therapy; 2018. Available from: https://ClinicalTrials.gov/show/NCT03616834. Accessed April 11, 2023.
   Google Scholar
• Therapeutics E, Medpace I. Tomivosertib combined with pembrolizumab in subjects with PD-L1 positive NSCLC (KICKSTART). Available from: https://ClinicalTrials.gov/show/NCT04622007;. Accessed April 11, 2023.2021.
   Google Scholar
• Therapeutics E, Merck KGaA D, Germany, Pfizer. A study to evaluate eFT508 alone and in combination with avelumab in subjects with MSS colorectal cancer; 2017. Available from: https://ClinicalTrials.gov/show/NCT03258398. Accessed April 11, 2023.
   Google Scholar
• Therapeutics E. A PD study of oral eFT508 in subjects with advanced TNBC and HCC; 2017. Available from: https://ClinicalTrials.gov/show/NCT03318562. Accessed April 11, 2023.
   Google Scholar
• Chen EC, Gandler H, Tosic I, et al. Targeting MET and FGFR in relapsed or refractory acute myeloid leukemia: preclinical and clinical findings, and signal transduction correlates. Clin Cancer Res. 2023;29(5):878–887. doi:10.1158/1078-0432.CCR-22-2540
   PubMed Web of Science ®Google Scholar
• eFFECTOR therapeutics’ lead product candidate, eFT508, receives orphan designation from FDA for treatment of diffuse large B-cell lymphoma [press release] eFFECTOR Therapeutics; 2017. Available from: https://www.prnewswire.com/news-releases/effector-therapeutics-lead-product-candidate-eft508-receives-orphan-designation-from-fda-for-treatment-of-diffuse-large-b-cell-lymphoma-300420884.html. Accessed January 4, 2023.
   Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2019;49(D1):D1388–D1395. doi:10.1093/nar/gkaa971
   Web of Science ®Google Scholar